RMD: Distribution Expansion And Execution Discipline Will Drive Future Upside

ResMed's updated analyst price target has slipped by about $8 to reflect slightly more cautious assumptions on revenue growth, profit margins, discount rate and future P/E, with several firms trimming targets even as others maintain a constructive view.

Analyst Commentary

Recent Street research on ResMed has tilted more cautious on valuation, even as one major firm has initiated with a bullish stance. For you as an investor, the key takeaway is that there is a clear split between analysts who see attractive growth and execution potential and those who are more focused on downside risks to valuation assumptions.

Bullish Takeaways

JPMorgan's bullish initiation signals that some analysts still see a constructive long term growth story, with current levels viewed as reasonable for building exposure based on their assumptions.
Bullish analysts point to what they view as solid execution potential, arguing that if management delivers on operational goals, current P/E assumptions can remain supported in their models.
Supportive commentary highlights opportunities for continued revenue expansion over time, which, if achieved, could justify premium valuation multiples in their scenarios.
The earlier US$15 price target increase from one firm suggests that there is still a cohort of analysts willing to raise valuation frameworks when they see stronger company specific drivers.

Bearish Takeaways

Several bearish analysts have trimmed price targets by US$5 to US$45, indicating more conservative views on what they are willing to pay for ResMed based on their revised growth and margin assumptions.
Lowered targets point to concerns around execution risk, where any shortfall versus expectations could pressure earnings trajectories and lead to further revisions in their models.
More cautious research notes suggest that prior valuation multiples may have embedded optimistic scenarios on revenue growth and profitability, so new targets reflect a reset to what they view as more balanced assumptions.
The cluster of recent target reductions implies that, while the long term story may still be intact for some, a larger share of the Street is now emphasizing risk control and tighter return hurdles when assessing ResMed.

What's in the News

ResMed announced that long serving Chief Financial Officer Brett Sandercock plans to retire effective May 4, 2026, and will remain as an advisor to the CEO through the end of calendar year 2027 (Key Developments).
Aaron Bloomer has been appointed as ResMed's next Chief Financial Officer, joining from Exact Sciences with more than 17 years of global finance and operating leadership experience across Exact Sciences, Baxter International and 3M (Key Developments).
ResMed is opening a new distribution center in Greenwood, Indiana, expected to begin operations in 2027 and serve as a major logistics hub to support patients and providers across North America (Key Developments).
The Greenwood facility is expected to employ more than 100 full time and contingent workers over time and is designed to complement existing distribution centers in Atlanta, Georgia and Moreno Valley, California (Key Developments).
Once fully operational, the Greenwood hub is planned to increase two day transit coverage across North America from 75% to 90% and shorten delivery times to Canada by one full day, based on the company’s estimates (Key Developments).

Valuation Changes

Fair Value: trimmed from $296.53 to $288.21, a reduction of about 2.8% in the updated model.
Discount Rate: adjusted slightly higher from 7.83% to 7.85%, implying a modestly higher required return in the analysis.
Revenue Growth: eased from 7.87% to 7.60%, reflecting a small step down in forecast top line expansion.
Net Profit Margin: nudged lower from 29.07% to 28.82%, indicating a slightly less optimistic earnings margin assumption.
Future P/E: brought down from 26.80x to 26.49x, indicating a marginally more conservative valuation multiple in the forecasts.

25 views

Key Takeaways

Strategic acquisitions, innovation, and digital health adoption are broadening market reach, deepening customer retention, and driving resilient revenue and margin growth.
Operational efficiencies and increased awareness in sleep health strengthen competitive advantages, fueling long-term earnings expansion and greater profitability.
Competitive, regulatory, and market shifts threaten ResMed's pricing power, market share, and profitability, especially as its hardware-focused model faces digital disruption and rising compliance costs.

Catalysts

About ResMed

Develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.What are the underlying business or industry changes driving this perspective?

Strategic investments in expanding the diagnosis and treatment funnel-including acquisitions like VirtuOx, Ectosense, and Somnoware-are improving patient flow from screening to therapy, positioning ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market, supporting long-term revenue growth.
Increased global awareness of sleep health issues, amplified by direct-to-consumer marketing campaigns and education programs for primary care physicians, is driving higher diagnosis and treatment rates, translating to elevated demand for ResMed's products and sustained top-line revenue growth.
Acceleration in adoption of home-based, cloud-connected therapy solutions and digital health platforms (including software like Brightree and AirView) enhances recurring high-margin revenue streams and increases both user retention and net profit margins over time.
Ongoing innovation in product development-including new releases of CPAP devices, mask interfaces, and integration of AI-driven features-strengthens ResMed's competitive differentiation and supports premium pricing power, driving both revenue and margin expansion.
Optimization initiatives in procurement, manufacturing, and logistics-along with the build-out of the U.S. manufacturing footprint-are structurally improving gross margins, which, when combined with operating leverage from global scale, are expected to boost overall earnings and free cash flow.

ResMed Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming ResMed's revenue will grow by 7.6% annually over the next 3 years.
Analysts assume that profit margins will increase from 27.5% today to 28.8% in 3 years time.
Analysts expect earnings to reach $1.9 billion (and earnings per share of $13.54) by about May 2029, up from $1.5 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $2.2 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.7x on those 2029 earnings, up from 20.9x today. This future PE is greater than the current PE for the AU Medical Equipment industry at 23.8x.
Analysts expect the number of shares outstanding to decline by 0.65% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.85%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The potential resumption or tightening of CMS competitive bidding programs in the US could pressure pricing and reimbursement rates for ResMed's core devices, leading to reduced revenue growth and compressed net margins.
Intensifying competition in the sleep apnea and respiratory market-including from alternative therapies such as GLP-1 drugs and hypoglossal nerve stimulators-may slow device adoption and erode ResMed's market share, negatively impacting topline revenue and margins.
Heavy dependence on positive secular trends (aging population, home-based care, and sleep disorder prevalence) exposes ResMed to risk if healthcare cost containment or stricter reimbursement policies emerge globally, which could limit growth and pressure earnings.
The accelerating transition toward digital and preventative health, as well as commoditization of respiratory medical equipment, may lower average selling prices and challenge ResMed's hardware-centric business model, impacting net margin expansion and longer-term profitability.
Rising regulatory and compliance demands-especially related to data privacy, cybersecurity, and evolving healthcare software oversight-could increase R&D and SG&A costs, pose legal risks, and potentially delay new product launches, putting pressure on future earnings and operating leverage.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $288.21 for ResMed based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $345.0, and the most bearish reporting a price target of just $230.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $6.7 billion, earnings will come to $1.9 billion, and it would be trading on a PE ratio of 26.7x, assuming you use a discount rate of 7.8%.
Given the current share price of $213.81, the analyst price target of $288.21 is 25.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ResMed?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge

RMD: Distribution Expansion And Execution Discipline Will Drive Future Upside